nalidixic acid has been researched along with Bacterial Disease in 86 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 3-day course of a new citrated formulation of nalidixic acid (Mictral) was assessed in fifty-four women presenting with acute uncomplicated cystitis." | 9.05 | A new citrated formulation of nalidixic acid (Mictral U.K.) for the treatment of acute cystitis. ( Adam, G; Allenby, F; Anderson, AR; Clark-Jones, A; Cure, SM; Dulake, C, 1981) |
| "To study whether oral ciprofloxacin would be as effective in preventing bacterial infections in severely myelosuppressed patients as selective antibiotic modulation of the gut flora with neomycin/polymyxin B sulfate/nalidixic acid (NPN)." | 5.07 | Infection prevention in severely myelosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora. ( Akard, L; Allen, SD; Black, JR; Cromer, M; Jansen, J; Wheat, LJ, 1994) |
| "Eighty-four cancer patients at risk of infection because of neutropenia were randomized to receive nalidixic acid as an alternative to trimethoprim-sulfamethoxazole (TMP-SMX) for infection prophylaxis." | 5.06 | Selective gut decontamination with nalidixic acid or trimethoprim-sulfamethoxazole for infection prophylaxis in neutropenic cancer patients: relationship of efficacy to antimicrobial spectrum and timing of administration. ( Bow, EJ; Louie, TJ; Rayner, E; Scott, BA, 1987) |
| "Sixty-two profoundly granulocytopenic patients with acute leukemia undergoing induction chemotherapy were prospectively randomized to receive either trimethoprim-sulfamethoxazole plus nystatin or nalidixic acid plus nystatin for prevention of infection." | 5.05 | Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid. ( Crowley, J; de Jongh, CA; Newman, KA; Schimpff, SC; Wade, JC; Wiernik, PH, 1983) |
| "A 3-day course of a new citrated formulation of nalidixic acid (Mictral) was assessed in fifty-four women presenting with acute uncomplicated cystitis." | 5.05 | A new citrated formulation of nalidixic acid (Mictral U.K.) for the treatment of acute cystitis. ( Adam, G; Allenby, F; Anderson, AR; Clark-Jones, A; Cure, SM; Dulake, C, 1981) |
| "Treatment with nalidixic acid during pregnancy may increase the risk of pyloric stenosis, though the chance effects cannot be excluded." | 3.71 | A population-based case-control teratologic study of nalidixic acid. ( Czeizel, AE; Olsen, J; Rockenbauer, M; Sørensen, HT, 2001) |
| "Systemic bacterial infections due to Escherichia coli MB 2884, Proteus mirabilis MB 3125 and Klebsiella pneumoniae MB 4005 were well controlled by treatment with norfloxacin both in normal and streptozotocin-induced diabetic mice." | 3.67 | Antibacterial efficacy of norfloxacin, trimethoprim-sulfamethoxazole, and gentamicin in experimentally-infected normal and streptozotocin-induced diabetic mice. ( Abruzzo, GK; Fromtling, RA; Gadebusch, HH, 1984) |
| " They are well absorbed after oral administration, and some achieve serum and tissue levels well exceeding the minimal inhibitory concentrations for susceptible bacteria." | 2.37 | Symposium on antimicrobial agents. The quinolones. ( Walker, RC; Wright, AJ, 1987) |
| "Diarrhea is the leading cause of morbidity and mortality in under-five children in developing countries including Ethiopia." | 1.40 | Prevalence of Shigella, Salmonella and Campylobacter species and their susceptibility patters among under five children with diarrhea in Hawassa town, south Ethiopia. ( Beyene, G; Mulatu, G; Zeynudin, A, 2014) |
| "Norfloxacin was least active against Clostridium difficile (90% minimal inhibitory concentration, 128 micrograms/ml)." | 1.27 | In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. ( Gadebusch, HH; Shungu, DL; Weinberg, E, 1983) |
| "Norfloxacin was the most active agent in the study on a weight-for-weight basis." | 1.27 | Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens. ( Dibb, WL; Digranes, A; Ostervold, B, 1984) |
| "Ciprofloxacin was 2-8 fold more active than norfloxacin and 100-fold more active than nalidixic acid." | 1.27 | The in vitro and in vivo activity of ciprofloxacin. ( Grohe, K; Zeiler, HJ, 1984) |
| "Enoxacin was active against staphylococci (MICs less than or equal to 4 mg/l) but less active against Streptococcus faecalis (MICs mostly 8 mg/l)." | 1.27 | In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates. ( Duncan, IB; Marshall, PW; Skulnick, M, 1984) |
| "Ciprofloxacin was the most active quinolone tested against both gentamicin-susceptible and gentamicin-resistant stains, having an MIC90 equal or less than 1 mg/l for all species studied." | 1.27 | The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients. ( Guimaraes, MA; Noone, P, 1986) |
| "Norfloxacin is a quinolinecarboxylic acid compound." | 1.26 | In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. ( Labthavikul, P; Neu, HC, 1982) |
| " The dose-response curve of AM-715 indicated a steep gradient, and the 50% inhibited doses of AM-715 were 0." | 1.26 | In vitro antibacterial activity of AM-715, a new nalidixic acid analog. ( Hirai, K; Inoue, M; Irikura, T; Ito, A; Koga, H; Mitsuhashi, S; Suzue, S, 1980) |
| "Miloxacin was more active than oxolinic acid against some anaerobes and less active against staphylococci." | 1.26 | Antibacterial activity of miloxacin. ( Eda, Y; Irie, K; Izawa, A; Kisaki, Y; Komatsu, T; Nakagome, T, 1980) |
| "Nalidixic acid is effective toward Gram negative infections but its short half-life and potential neurological toxicity explain that its parenteral use is hazardous." | 1.26 | [The pharmacokinetics of nalidixic acid administered parenterally. Towards rational use in severe infections (author's transl)]. ( d'Athis, P; Houin, G; Lartigue, C; Lhoste, F; Rapin, M; Tillement, JP, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 75 (87.21) | 18.7374 |
| 1990's | 2 (2.33) | 18.2507 |
| 2000's | 5 (5.81) | 29.6817 |
| 2010's | 3 (3.49) | 24.3611 |
| 2020's | 1 (1.16) | 2.80 |
| Authors | Studies |
|---|---|
| Matsumoto, J | 1 |
| Miyamoto, T | 1 |
| Minamida, A | 1 |
| Nishimura, Y | 1 |
| Egawa, H | 1 |
| Nishimura, H | 1 |
| Miller, AA | 1 |
| Bundy, GL | 1 |
| Mott, JE | 1 |
| Skepner, JE | 1 |
| Boyle, TP | 1 |
| Harris, DW | 1 |
| Hromockyj, AE | 1 |
| Marotti, KR | 1 |
| Zurenko, GE | 1 |
| Munzner, JB | 1 |
| Sweeney, MT | 1 |
| Bammert, GF | 1 |
| Hamel, JC | 1 |
| Ford, CW | 1 |
| Zhong, WZ | 1 |
| Graber, DR | 1 |
| Martin, GE | 1 |
| Han, F | 1 |
| Dolak, LA | 1 |
| Seest, EP | 1 |
| Ruble, JC | 1 |
| Kamilar, GM | 1 |
| Palmer, JR | 1 |
| Banitt, LS | 1 |
| Hurd, AR | 1 |
| Barbachyn, MR | 1 |
| Ben Salem, A | 1 |
| Sautrey, G | 1 |
| Fontanay, S | 1 |
| Duval, RE | 1 |
| Regnouf-de-Vains, JB | 1 |
| Bisacchi, GS | 1 |
| Angst, DC | 1 |
| Tepekule, B | 1 |
| Sun, L | 1 |
| Bogos, B | 1 |
| Bonhoeffer, S | 1 |
| Mulatu, G | 1 |
| Beyene, G | 1 |
| Zeynudin, A | 1 |
| Piddock, LJ | 1 |
| Johnson, MM | 1 |
| Webber, MA | 1 |
| DUCASSOU, J | 1 |
| RICHAUD, C | 1 |
| BENADY, F | 1 |
| LATOURELLE, P | 1 |
| Sable, D | 1 |
| Murakawa, GJ | 1 |
| Newsom, SW | 1 |
| Matthews, J | 1 |
| Amphlett, M | 1 |
| Warren, RE | 1 |
| Neu, HC | 1 |
| Labthavikul, P | 1 |
| Shungu, DL | 1 |
| Weinberg, E | 1 |
| Gadebusch, HH | 2 |
| Rylander, M | 1 |
| Norrby, SR | 1 |
| Bailey, RR | 1 |
| Peddie, BA | 1 |
| Blake, E | 1 |
| Chartrand, SA | 1 |
| Scribner, RK | 1 |
| Weber, AH | 1 |
| Welch, DF | 1 |
| Marks, MI | 1 |
| Nakamura, S | 2 |
| Nakata, K | 1 |
| Katae, H | 2 |
| Minami, A | 2 |
| Kashimoto, S | 1 |
| Yamagishi, J | 1 |
| Takase, Y | 1 |
| Shimizu, M | 2 |
| Kouno, K | 1 |
| Inoue, M | 3 |
| Mitsuhashi, S | 3 |
| Digranes, A | 1 |
| Dibb, WL | 1 |
| Ostervold, B | 1 |
| Zeiler, HJ | 1 |
| Grohe, K | 1 |
| Bauernfeind, A | 1 |
| Ullmann, U | 1 |
| Fromtling, RA | 1 |
| Abruzzo, GK | 1 |
| Hendriks, WD | 1 |
| Sizoo, W | 1 |
| Löwenberg, B | 1 |
| Hagenbeek, A | 1 |
| Duncan, IB | 1 |
| Skulnick, M | 1 |
| Marshall, PW | 1 |
| Ito, A | 2 |
| Hirai, K | 2 |
| Koga, H | 1 |
| Suzue, S | 2 |
| Irikura, T | 2 |
| Abe, Y | 1 |
| Gussmann, S | 1 |
| Hanno, M | 1 |
| Shofer, F | 1 |
| Fritz, R | 1 |
| Mulholland, SG | 1 |
| Wein, AJ | 1 |
| Wade, JC | 1 |
| de Jongh, CA | 1 |
| Newman, KA | 1 |
| Crowley, J | 1 |
| Wiernik, PH | 1 |
| Schimpff, SC | 2 |
| Varese, LA | 1 |
| Girazioli, F | 1 |
| Tapparo, D | 1 |
| Viretto, A | 1 |
| Antoniola, P | 1 |
| Dulake, C | 1 |
| Adam, G | 1 |
| Allenby, F | 1 |
| Anderson, AR | 1 |
| Clark-Jones, A | 1 |
| Cure, SM | 1 |
| Handrick, W | 1 |
| Bergmann, L | 1 |
| Spencker, FB | 1 |
| Wilson, KH | 1 |
| Sheagren, JN | 1 |
| Freter, RG | 1 |
| Popov, N | 1 |
| Drylie, DM | 1 |
| Migliori, V | 1 |
| Londei, M | 1 |
| Bonazzi, A | 1 |
| Cavaciocchi, P | 1 |
| Cuppini, S | 1 |
| Izawa, A | 1 |
| Kisaki, Y | 1 |
| Irie, K | 1 |
| Eda, Y | 1 |
| Nakagome, T | 1 |
| Komatsu, T | 1 |
| Jansen, J | 1 |
| Cromer, M | 1 |
| Akard, L | 1 |
| Black, JR | 1 |
| Wheat, LJ | 1 |
| Allen, SD | 1 |
| Gomis, M | 1 |
| Ledesma, F | 1 |
| Cahen, P | 1 |
| Honderlick, P | 1 |
| Czeizel, AE | 1 |
| Sørensen, HT | 1 |
| Rockenbauer, M | 1 |
| Olsen, J | 1 |
| McHenry, MC | 1 |
| Gavan, TL | 1 |
| Eichenwald, HF | 1 |
| McCracken, GH | 1 |
| Cancet, B | 1 |
| Balogh, F | 1 |
| Köves, S | 1 |
| Kocsis, B | 1 |
| Albrecht, R | 1 |
| Gray, BM | 1 |
| Pass, MA | 1 |
| Dillon, HC | 1 |
| Tillement, JP | 1 |
| Houin, G | 1 |
| Lhoste, F | 1 |
| d'Athis, P | 1 |
| Lartigue, C | 1 |
| Rapin, M | 1 |
| Schilirò, S | 1 |
| D'Asta, S | 1 |
| Pagani, G | 1 |
| Steele, TW | 1 |
| Rich, GE | 1 |
| Courtine, JC | 1 |
| Blot, P | 1 |
| Jones, RN | 1 |
| Fuchs, PC | 1 |
| Sorice, F | 1 |
| Ortona, L | 1 |
| Pizzigallo, E | 1 |
| Takdase, Y | 1 |
| Khoshoo, V | 1 |
| Raj, P | 1 |
| Srivastava, R | 1 |
| Bhandari, N | 1 |
| Sazawal, S | 1 |
| Bhatnager, S | 1 |
| Bhan, MK | 1 |
| Klietmann, W | 1 |
| Focht, J | 1 |
| Nösner, K | 1 |
| Guimaraes, MA | 1 |
| Noone, P | 1 |
| Desplaces, N | 1 |
| Gutmann, L | 1 |
| Carlet, J | 1 |
| Guibert, J | 1 |
| Acar, JF | 1 |
| Høiby, N | 1 |
| Bischoff, W | 1 |
| Modde, H | 2 |
| Kling, PA | 1 |
| Burman, LG | 1 |
| Bow, EJ | 1 |
| Rayner, E | 1 |
| Scott, BA | 1 |
| Louie, TJ | 1 |
| Walker, RC | 1 |
| Wright, AJ | 1 |
| Wolff, M | 1 |
| Karachalios, GN | 1 |
| Georgiopoulos, AN | 1 |
| Burke, TL | 1 |
| Helms, CM | 1 |
| Bláha, M | 1 |
| Vacková, M | 1 |
| Vanásek, J | 1 |
| Splino, M | 1 |
| Jebavý, L | 1 |
| Malý, J | 1 |
| Pecka, M | 1 |
| Macfarlane, DE | 1 |
| Greenwood, D | 2 |
| Cox, CE | 1 |
| Zahradnický, J | 1 |
| Roemer, GB | 1 |
| Matz, K | 1 |
| Höffler, D | 1 |
| Asnes, RS | 1 |
| Grebin, B | 1 |
| Agoston, E | 1 |
| Balogh, E | 1 |
| Simon, L | 1 |
| Farkas, G | 1 |
| Fairley, KF | 1 |
| Wick, WE | 1 |
| Preston, DA | 1 |
| White, WA | 1 |
| Gordee, RS | 1 |
| Schortgen, G | 1 |
| Tancrede, C | 1 |
| Goulon, M | 1 |
| Lissac, J | 1 |
| Labrousse, J | 1 |
| Estampes, B | 1 |
| Kiss, J | 1 |
| Faragó, E | 1 |
| Fábián, E | 1 |
| Prát, V | 1 |
| Kondás, J | 1 |
10 reviews available for nalidixic acid and Bacterial Disease
| Article | Year |
|---|---|
Origins of the Quinolone Class of Antibacterials: An Expanded "Discovery Story".
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Discovery; History, 20th Centur | 2015 |
Quinolones in dermatology.
Topics: Anti-Infective Agents; Area Under Curve; Bacterial Infections; Biological Availability; Ciprofloxaci | 2004 |
[Bacteriologic management of patients with decreased resistance].
Topics: Agranulocytosis; Anti-Bacterial Agents; Antisepsis; Bacterial Infections; Drug Combinations; Humans; | 1984 |
Selection and use of antibacterial drugs.
Topics: Aminoglycosides; Anti-Infective Agents; Bacterial Infections; Cephalosporins; Chloramphenicol; Drug | 1975 |
Antimicrobial therapy in infants and children. Part I. Review of antimicrobial agents.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacitracin; Bacterial Infections; Cephalosporins; Child; Chi | 1978 |
Development of antibacterial agents of the nalidixic acid type.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Chemistry, Pharmaceutical; Drug Eval | 1977 |
The new quinolones and their combinations with other agents for therapy of severe infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; DNA Replication; Drug Resistance, Microbial; Drug Syner | 1986 |
Symposium on antimicrobial agents. The quinolones.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1987 |
Prevention and treatment of catheter-associated urinary tract infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Bacteriuria; Catheters, Indwelling; Cross Infection; Hu | 1985 |
Symposium on renal lithiasis. Urinary tract infection and renal lithiasis.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbenicillin; Cephalosporins; Chloramphenicol; Humans; | 1974 |
9 trials available for nalidixic acid and Bacterial Disease
| Article | Year |
|---|---|
Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Child; Drug Combinations; Female; Hu | 1983 |
A new citrated formulation of nalidixic acid (Mictral U.K.) for the treatment of acute cystitis.
Topics: Acute Disease; Adolescent; Adult; Bacterial Infections; Clinical Trials as Topic; Cystitis; Female; | 1981 |
Cinoxacin and nalidixic acid in treatment of urinary tract infections.
Topics: Bacterial Infections; Cinoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Pyridazines; U | 1981 |
Infection prevention in severely myelosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Bone Marrow Diseases; Ciprofloxacin; Drug Therapy, Co | 1994 |
Examinations with oxolinic acid and nalidixic acid: (comparative study on the in vitro and therapeutic action).
Topics: Bacterial Infections; Clinical Trials as Topic; Humans; Nalidixic Acid; Oxolinic Acid; Urinary Tract | 1977 |
[Pipemidic acid in the treatment of various infective disorders of the urinary tract in a series of obstetric and gynecologic patients].
Topics: Adult; Bacterial Infections; Female; Genital Diseases, Female; Humans; Nalidixic Acid; Nicotinic Aci | 1979 |
Failure of single-dose metronidazole prophylaxis in colorectal surgery. No benefit from high dosage or combination with nalidixic acid.
Topics: Adult; Aged; Bacterial Infections; Clinical Trials as Topic; Colon; Drug Therapy, Combination; Femal | 1988 |
Selective gut decontamination with nalidixic acid or trimethoprim-sulfamethoxazole for infection prophylaxis in neutropenic cancer patients: relationship of efficacy to antimicrobial spectrum and timing of administration.
Topics: Agranulocytosis; Antineoplastic Agents; Bacteria; Bacterial Infections; Clinical Trials as Topic; Dr | 1987 |
Norfloxacin versus nalidixic acid in the treatment of urinary tract infections.
Topics: Adult; Aged; Bacterial Infections; Bacteriuria; Female; Humans; Male; Middle Aged; Nalidixic Acid; N | 1987 |
67 other studies available for nalidixic acid and Bacterial Disease
| Article | Year |
|---|---|
Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Enoxacin; Escherichia coli; Mice; Naphthyridin | 1984 |
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacteria; Bacterial Infections; Bacterial Proteins | 2008 |
Molecular drug-organiser: synthesis, characterization and biological evaluation of penicillin V and/or nalidixic acid calixarene-based podands.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Calixarenes; Humans; Microbial Sensitivity Te | 2011 |
Comparing treatment strategies to reduce antibiotic resistance in an in vitro epidemiological setting.
Topics: Adaptation, Physiological; Anti-Bacterial Agents; Bacterial Infections; Computer Simulation; Drug Re | 2021 |
Prevalence of Shigella, Salmonella and Campylobacter species and their susceptibility patters among under five children with diarrhea in Hawassa town, south Ethiopia.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Campylobacter; Ceftriaxone; Ch | 2014 |
Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactams; Ciprofloxacin; Drug Resistance, | 2003 |
[A NEW URINARY ANTISEPTIC ACTIVE IN GRAM-NEGATIVE BACTERIAL INFECTIONS].
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Nalidixic Acid; Naphthy | 1965 |
Norfloxacin and the antibacterial gamma pyridone beta carboxylic acids.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Humans; Microbial Sensitivity Tests; Nalidixi | 1982 |
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactams; Microbial Sens | 1982 |
In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Digestive System; Drug Combinations; Drug Res | 1983 |
Norfloxacin penetration into subcutaneous tissue cage fluid in rabbits and efficacy in vivo.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Escherichia coli Infections; Klebsiella Infect | 1983 |
Norfloxacin for the treatment of uncomplicated urinary tract infections.
Topics: Adult; Bacterial Infections; Drug Evaluation; Female; Humans; Nalidixic Acid; Norfloxacin; Urinary T | 1983 |
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Stability; Enoxacin; Humans; Microbial S | 1983 |
Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Enoxacin; Gentamicins; Male; Mice; Nalidixic A | 1983 |
In vitro and in vivo antibacterial activity of AT-2266.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enoxacin | 1983 |
Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enterobacteriacea | 1984 |
The in vitro and in vivo activity of ciprofloxacin.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; | 1984 |
In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
Topics: Bacteria; Bacterial Infections; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Napht | 1984 |
Antibacterial efficacy of norfloxacin, trimethoprim-sulfamethoxazole, and gentamicin in experimentally-infected normal and streptozotocin-induced diabetic mice.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Diabetes Mellitus, Experimental; Dru | 1984 |
In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Drug Resistance, Microbial; Enoxacin; | 1984 |
In vitro antibacterial activity of AM-715, a new nalidixic acid analog.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Culture Media; Drug Resistance, Microbial; Hu | 1980 |
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Mice; Nalidixic Acid; Nicotinic Acids; Norflox | 1981 |
[Therapy of urinary tract infections: striking Gram-negative germs. Changes in the bacterial spectrum and resistance in a group of patients over an 18-year period].
Topics: Anti-Bacterial Agents; Bacterial Infections; Clotrimazole; Drug Resistance, Microbial; Enterobacteri | 1983 |
Antimicrobial sensitivities in urinary tract infections in men.
Topics: Ampicillin; Bacterial Infections; Candida; Cephalosporins; Enterobacteriaceae; Escherichia coli; Gen | 1980 |
[Assessment of the correctness of the diagnosis and treatment of subjects hospitalized for urinary tract infections in clinics and hospitals].
Topics: Age Factors; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Child; Chi | 1982 |
[Perinatal infections caused by rare agents. 2. Serratia marcescens].
Topics: Bacterial Infections; Carbenicillin; Gentamicins; Humans; Infant, Newborn; Infant, Newborn, Diseases | 1981 |
Selective antimicrobial modulation of human microbial flora.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacterial Infections; Colon; Humans; Nalidixic Acid; Neutropeni | 1982 |
[Molecular biology aspects of the antimicrobial effect of synthetic chemotherapeutic agents].
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Biotransformation; Delayed-Action Pr | 1982 |
[Urinary tract infections in the involutive age. 2].
Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Drug Resistance, Microbial; Fema | 1981 |
Infection prevention during profound granulocytopenia. New approaches to alimentary canal microbial suppression.
Topics: Agranulocytosis; Air Microbiology; Anti-Bacterial Agents; Bacterial Infections; Cross Infection; Dru | 1980 |
Antibacterial activity of miloxacin.
Topics: 4-Quinolones; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Enterobacteriaceae; Mi | 1980 |
[The future of quinolones].
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Dogs; Drug Interactions; Drug Resistance, Micr | 1996 |
[Nitrofurans: a modern treatment for uncomplicated urinary infections?].
Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Drug Resistance, Microbial; Enterobacteriaceae | 2000 |
A population-based case-control teratologic study of nalidixic acid.
Topics: Abnormalities, Drug-Induced; Adult; Anti-Infective Agents; Bacterial Infections; Case-Control Studie | 2001 |
The effect of nalidixic acid on microaerophilic and anaerobic bacteria. Special study of clostridia.
Topics: Anaerobiosis; Bacteria; Bacterial Infections; Clostridium; Clostridium perfringens; Drug Resistance, | 1979 |
Laboratory and field evaluation of selective media for isolation of group B streptococci.
Topics: Bacteria; Bacterial Infections; Culture Media; Gentamicins; Humans; Infant, Newborn; Infant, Newborn | 1979 |
[The pharmacokinetics of nalidixic acid administered parenterally. Towards rational use in severe infections (author's transl)].
Topics: Bacterial Infections; Half-Life; Humans; Infusions, Parenteral; Injections, Intravenous; Nalidixic A | 1979 |
[Use of pipemidic acid in the treatment of urinary tract infections].
Topics: Adult; Aged; Bacterial Infections; Cystitis; Female; Humans; Male; Middle Aged; Nalidixic Acid; Nico | 1979 |
The rational use of antibiotics in general practice.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Clindamycin; Drug Combinations; Epididy | 1977 |
[Letter: Serratia marcescens septicemia treated by nalidixic acid in perfusion].
Topics: Adult; Bacterial Infections; Humans; Injections, Intravenous; Male; Nalidixic Acid; Remission, Spont | 1976 |
In vitro antimicrobial activity of cinoxacin against 2,968 clinical bacterial isolates.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Dioxolanes; Humans; Nalidixic Acid; Pyridazin | 1976 |
[Further aspects of combination antibiotic therapy. Critical review and personal case studies].
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Brucellosis; Drug Interactions; Drug Thera | 1975 |
Pipemidic acid: its activities against various experimental infections.
Topics: Ampicillin; Animals; Anti-Infective Agents; Bacterial Infections; Carbenicillin; Cephalexin; Female; | 1976 |
Efficacy of nalidixic acid in the treatment of acute bloody diarrhea.
Topics: Acute Disease; Bacterial Infections; Child, Preschool; Diarrhea; Diarrhea, Infantile; Humans; Infant | 1989 |
Comparative in vitro activity of ciprofloxacin against aerobic and anaerobic bacteria from clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Ciprofloxacin; | 1987 |
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
Topics: Acinetobacter; Bacteria; Bacterial Infections; Ciprofloxacin; Citrobacter; Drug Resistance, Microbia | 1986 |
Clinical uses of nalidixic acid analogues: the fluoroquinolones.
Topics: Administration, Oral; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Evaluation; D | 1986 |
[Norfloxacin treatment of acute cystitis in the female and bacterial prostatitis].
Topics: Adult; Anti-Infective Agents, Urinary; Bacterial Infections; Cystitis; Female; Humans; Male; Microbi | 1985 |
[Norfloxacin sensitivity of bacterial pathogens of urinary tract infections].
Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Humans; Microbial Sensitivity Tests; Nalidixic | 1985 |
[Therapeutic contribution of the new quinolones].
Topics: Anti-Infective Agents; Bacterial Infections; Biotransformation; Chemical Phenomena; Chemistry; Cipro | 1987 |
The fluoroquinolone antibiotics: clinical indications and implications of several new derivatives of nalidixic acid.
Topics: Anti-Infective Agents; Bacterial Infections; Humans; Nalidixic Acid | 1987 |
[Selective decontamination of the digestive tract for the prevention of infection in patients with neutropenia].
Topics: Adult; Agranulocytosis; Anti-Infective Agents; Bacterial Infections; Digestive System; Humans; Mycos | 1986 |
An in-vitro model simulating the hydrokinetic aspects of the treatment of bacterial cystitis.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cystitis; Drug Resistance, Microbial | 1985 |
Prospects for new antibiotics: keeping one step ahead.
Topics: Aminoglycosides; Anthelmintics; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bac | 1985 |
[Laboratory control of chemotherapy].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbenicillin; Culture Media; Humans; Nalidix | 1972 |
[Bacteriological aspects of current antibacterial chemotherapy].
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Cephaloridine; Cephalosporins; Cephalothin; | 1972 |
[Antibiotic therapy].
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Chloramphenicol; Colistin; Drug Therapy | 1973 |
Practical antibiotic therapy in children.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Child; Chloramphenicol; Ery | 1973 |
[Diseases caused by Serratia marcescens (Prodigiosus)].
Topics: Bacterial Infections; Carbenicillin; Chloramphenicol; Cross Infection; Enterobacteriaceae Infections | 1972 |
Changes in resistance of the bacterial flora among patients seen at the Ist department of surgery of the Szeged University during the past 5 years.
Topics: Ampicillin; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacteriuria; Chloramphenicol; Col | 1974 |
Diagnosis and treatment of pyelonephritis.
Topics: Ampicillin; Bacterial Infections; Cephalexin; Erythromycin; Female; Gentamicins; Humans; Kidney Dise | 1973 |
Compound 64716, a new synthetic antibacterial agent.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carboxylic Acids; Dioxoles; Drug Sta | 1973 |
[New therapeutic possibility in severe gram negative bacillus infections].
Topics: Bacteria; Bacterial Infections; Drug Evaluation; Drug Resistance, Microbial; Drug Tolerance; Humans; | 1973 |
[Innovations in antibiotic therapy].
Topics: Aminoglycosides; Bacterial Infections; Cephalosporins; Clindamycin; Drug Combinations; Humans; Nalid | 1973 |
In vitro study and local application of nalidixic acid (Nevigramon).
Topics: Administration, Topical; Bacterial Infections; Escherichia coli; Humans; In Vitro Techniques; Microb | 1971 |
[Experimental chemotherapy].
Topics: Animals; Animals, Laboratory; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Disease Models, | 1972 |
Treatment of renal and urogenital infections with Nevigramon (nalidixic acid).
Topics: Bacterial Infections; Cystitis; Female; Humans; Kidney Diseases; Male; Nalidixic Acid; Prostatitis; | 1971 |